MXPA06011716A - Crystalline polymorph of a bazedoxifene acetate - Google Patents
Crystalline polymorph of a bazedoxifene acetateInfo
- Publication number
- MXPA06011716A MXPA06011716A MXPA/A/2006/011716A MXPA06011716A MXPA06011716A MX PA06011716 A MXPA06011716 A MX PA06011716A MX PA06011716 A MXPA06011716 A MX PA06011716A MX PA06011716 A MXPA06011716 A MX PA06011716A
- Authority
- MX
- Mexico
- Prior art keywords
- composition
- polymorph
- weight
- bazedoxifene acetate
- present
- Prior art date
Links
- OMZAMQFQZMUNTP-UHFFFAOYSA-N acetic acid;1-[[4-[2-(azepan-1-yl)ethoxy]phenyl]methyl]-2-(4-hydroxyphenyl)-3-methylindol-5-ol Chemical compound CC(O)=O.C=1C=C(OCCN2CCCCCC2)C=CC=1CN1C2=CC=C(O)C=C2C(C)=C1C1=CC=C(O)C=C1 OMZAMQFQZMUNTP-UHFFFAOYSA-N 0.000 title claims abstract description 144
- 229960003713 bazedoxifene acetate Drugs 0.000 title claims abstract description 144
- 239000000203 mixture Substances 0.000 claims abstract description 213
- 238000002360 preparation method Methods 0.000 claims abstract description 17
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 64
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 33
- XEKOWRVHYACXOJ-UHFFFAOYSA-N acetic acid ethyl ester Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 32
- 201000010099 disease Diseases 0.000 claims description 32
- 239000000262 estrogen Substances 0.000 claims description 18
- 241000124008 Mammalia Species 0.000 claims description 14
- 238000000113 differential scanning calorimetry Methods 0.000 claims description 14
- 239000002904 solvent Substances 0.000 claims description 14
- 239000011541 reaction mixture Substances 0.000 claims description 13
- UCJGJABZCDBEDK-UHFFFAOYSA-N Bazedoxifene Chemical compound C=1C=C(OCCN2CCCCCC2)C=CC=1CN1C2=CC=C(O)C=C2C(C)=C1C1=CC=C(O)C=C1 UCJGJABZCDBEDK-UHFFFAOYSA-N 0.000 claims description 12
- 229960000817 bazedoxifene Drugs 0.000 claims description 12
- 238000000634 powder X-ray diffraction Methods 0.000 claims description 11
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Vitamin C Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 10
- 229960005070 ascorbic acid Drugs 0.000 claims description 10
- 239000003963 antioxidant agent Substances 0.000 claims description 9
- 235000006708 antioxidants Nutrition 0.000 claims description 9
- 239000003814 drug Substances 0.000 claims description 9
- 238000005984 hydrogenation reaction Methods 0.000 claims description 9
- HVYWMOMLDIMFJA-DPAQBDIFSA-N (3β)-Cholest-5-en-3-ol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 8
- IOLCXVTUBQKXJR-UHFFFAOYSA-M potassium bromide Inorganic materials [K+].[Br-] IOLCXVTUBQKXJR-UHFFFAOYSA-M 0.000 claims description 8
- 210000001519 tissues Anatomy 0.000 claims description 8
- QTBSBXVTEAMEQO-UHFFFAOYSA-M acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 7
- 235000010323 ascorbic acid Nutrition 0.000 claims description 7
- 239000011668 ascorbic acid Substances 0.000 claims description 7
- 206010065687 Bone loss Diseases 0.000 claims description 6
- 230000003078 antioxidant Effects 0.000 claims description 6
- 239000003054 catalyst Substances 0.000 claims description 5
- 238000002329 infrared spectrum Methods 0.000 claims description 5
- 230000002401 inhibitory effect Effects 0.000 claims description 5
- GNVYSOYFHQFUMV-UHFFFAOYSA-N 3-(azepan-1-yl)-2-phenylmethoxy-1H-indole Chemical compound C=1C=CC=CC=1COC=1NC2=CC=CC=C2C=1N1CCCCCC1 GNVYSOYFHQFUMV-UHFFFAOYSA-N 0.000 claims description 4
- 206010006187 Breast cancer Diseases 0.000 claims description 4
- 229940107161 Cholesterol Drugs 0.000 claims description 4
- 239000003153 chemical reaction reagent Substances 0.000 claims description 4
- 235000012000 cholesterol Nutrition 0.000 claims description 4
- 230000002357 endometrial Effects 0.000 claims description 4
- 201000010874 syndrome Diseases 0.000 claims description 4
- 230000001457 vasomotor Effects 0.000 claims description 4
- 230000002159 abnormal effect Effects 0.000 claims description 3
- 229940035811 conjugated estrogens Drugs 0.000 claims description 3
- 239000012458 free base Substances 0.000 claims description 3
- 230000035755 proliferation Effects 0.000 claims description 3
- VUCAHVBMSFIGAI-ZFINNJDLSA-M estrone sodium sulfate Chemical compound [Na+].[O-]S(=O)(=O)OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 VUCAHVBMSFIGAI-ZFINNJDLSA-M 0.000 claims description 2
- 230000003637 steroidlike Effects 0.000 claims description 2
- 238000001228 spectrum Methods 0.000 claims 1
- 238000009472 formulation Methods 0.000 description 23
- 239000007884 disintegrant Substances 0.000 description 14
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 12
- 239000000945 filler Substances 0.000 description 11
- -1 2-azepan-1-yl-ethoxy Chemical group 0.000 description 10
- 235000019439 ethyl acetate Nutrition 0.000 description 10
- 210000000988 Bone and Bones Anatomy 0.000 description 9
- 239000000314 lubricant Substances 0.000 description 9
- 235000014113 dietary fatty acids Nutrition 0.000 description 8
- 239000000194 fatty acid Substances 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 229940079593 drugs Drugs 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 239000011780 sodium chloride Substances 0.000 description 7
- 235000002639 sodium chloride Nutrition 0.000 description 7
- QIQXTHQIDYTFRH-UHFFFAOYSA-N Stearic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 6
- 239000002775 capsule Substances 0.000 description 6
- 229910052751 metal Inorganic materials 0.000 description 6
- 239000002184 metal Substances 0.000 description 6
- 229910052757 nitrogen Inorganic materials 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 239000000556 agonist Substances 0.000 description 5
- VTYYLEPIZMXCLO-UHFFFAOYSA-L calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 5
- 238000002844 melting Methods 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- 229920002472 Starch Polymers 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 238000007792 addition Methods 0.000 description 4
- 230000035492 administration Effects 0.000 description 4
- 150000004665 fatty acids Chemical class 0.000 description 4
- 239000007888 film coating Substances 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 4
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 235000000346 sugar Nutrition 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- YXFVVABEGXRONW-UHFFFAOYSA-N toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 4
- 239000000080 wetting agent Substances 0.000 description 4
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 3
- 206010030247 Oestrogen deficiency Diseases 0.000 description 3
- 235000021355 Stearic acid Nutrition 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 230000000111 anti-oxidant Effects 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 235000010980 cellulose Nutrition 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- MOTZDAYCYVMXPC-UHFFFAOYSA-M dodecyl sulfate Chemical class CCCCCCCCCCCCOS([O-])(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-M 0.000 description 3
- 239000000328 estrogen antagonist Substances 0.000 description 3
- 238000009501 film coating Methods 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 3
- 230000001603 reducing Effects 0.000 description 3
- 239000000333 selective estrogen receptor modulator Substances 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- QIQXTHQIDYTFRH-UHFFFAOYSA-M stearate Chemical class CCCCCCCCCCCCCCCCCC([O-])=O QIQXTHQIDYTFRH-UHFFFAOYSA-M 0.000 description 3
- 239000008117 stearic acid Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 235000012222 talc Nutrition 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- CIWBSHSKHKDKBQ-DUZGATOHSA-N (+)-Ascorbic acid Natural products OC[C@@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-DUZGATOHSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N (E)-but-2-enedioate;hydron Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- WNLRTRBMVRJNCN-UHFFFAOYSA-N Adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 2
- XJKJWTWGDGIQRH-BFIDDRIFSA-N Alginic acid Chemical compound O1[C@@H](C(O)=O)[C@@H](OC)[C@H](O)[C@H](O)[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](C)[C@@H](O)[C@H]1O XJKJWTWGDGIQRH-BFIDDRIFSA-N 0.000 description 2
- 229960005069 Calcium Drugs 0.000 description 2
- 229960003563 Calcium Carbonate Drugs 0.000 description 2
- CJZGTCYPCWQAJB-UHFFFAOYSA-L Calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L Calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-KAZBKCHUSA-N D-Mannitol Natural products OC[C@@H](O)[C@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KAZBKCHUSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- OKMWKBLSFKFYGZ-UHFFFAOYSA-N Glyceryl behenate Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(O)CO OKMWKBLSFKFYGZ-UHFFFAOYSA-N 0.000 description 2
- 238000004566 IR spectroscopy Methods 0.000 description 2
- 239000002211 L-ascorbic acid Substances 0.000 description 2
- 235000000069 L-ascorbic acid Nutrition 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- GUBGYTABKSRVRQ-UUNJERMWSA-N Lactose Natural products O([C@@H]1[C@H](O)[C@H](O)[C@H](O)O[C@@H]1CO)[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1 GUBGYTABKSRVRQ-UUNJERMWSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M NaHCO3 Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 229940095743 Selective estrogen receptor modulators Drugs 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 229940032147 Starch Drugs 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- CZMRCDWAGMRECN-GDQSFJPYSA-N Sucrose Natural products O([C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1)[C@@]1(CO)[C@H](O)[C@@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-GDQSFJPYSA-N 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 239000000783 alginic acid Substances 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 229960001126 alginic acid Drugs 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000001833 anti-estrogenic Effects 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 235000001465 calcium Nutrition 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 235000013539 calcium stearate Nutrition 0.000 description 2
- 239000008116 calcium stearate Substances 0.000 description 2
- HENMSNJYDGNBMU-UHFFFAOYSA-M calcium;zinc;octadecanoate Chemical compound [Ca+2].[Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O HENMSNJYDGNBMU-UHFFFAOYSA-M 0.000 description 2
- 230000001076 estrogenic Effects 0.000 description 2
- 150000002191 fatty alcohols Chemical class 0.000 description 2
- 238000011010 flushing procedure Methods 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 229940049654 glyceryl behenate Drugs 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 239000008241 heterogeneous mixture Substances 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 2
- 238000007327 hydrogenolysis reaction Methods 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N iso-propanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000006011 modification reaction Methods 0.000 description 2
- 238000010899 nucleation Methods 0.000 description 2
- 239000002831 pharmacologic agent Substances 0.000 description 2
- 230000000704 physical effect Effects 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 238000001144 powder X-ray diffraction data Methods 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- 229940045902 sodium stearyl fumarate Drugs 0.000 description 2
- STFSJTPVIIDAQX-LTRPLHCISA-M sodium;(E)-4-octadecoxy-4-oxobut-2-enoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCCOC(=O)\C=C\C([O-])=O STFSJTPVIIDAQX-LTRPLHCISA-M 0.000 description 2
- 239000012265 solid product Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 229960002920 sorbitol Drugs 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 239000000230 xanthan gum Substances 0.000 description 2
- 235000010493 xanthan gum Nutrition 0.000 description 2
- 229920001285 xanthan gum Polymers 0.000 description 2
- 229940082509 xanthan gum Drugs 0.000 description 2
- ONBWNNUYXGJKKD-UHFFFAOYSA-N 1,4-bis(2-ethylhexoxy)-1,4-dioxobutane-2-sulfonic acid;sodium Chemical compound [Na].CCCCC(CC)COC(=O)CC(S(O)(=O)=O)C(=O)OCC(CC)CCCC ONBWNNUYXGJKKD-UHFFFAOYSA-N 0.000 description 1
- AFABGHUZZDYHJO-UHFFFAOYSA-N 2-Methylpentane Chemical class CCCC(C)C AFABGHUZZDYHJO-UHFFFAOYSA-N 0.000 description 1
- 125000004203 4-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 206010000496 Acne Diseases 0.000 description 1
- 208000005641 Adenomyosis Diseases 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- PZZYQPZGQPZBDN-UHFFFAOYSA-N Aluminium silicate Chemical compound O=[Al]O[Si](=O)O[Al]=O PZZYQPZGQPZBDN-UHFFFAOYSA-N 0.000 description 1
- 206010001897 Alzheimer's disease Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- PRKQVKDSMLBJBJ-UHFFFAOYSA-N Ammonium carbonate Chemical compound N.N.OC(O)=O PRKQVKDSMLBJBJ-UHFFFAOYSA-N 0.000 description 1
- 206010068168 Androgenetic alopecia Diseases 0.000 description 1
- 241000272517 Anseriformes Species 0.000 description 1
- 229960005261 Aspartic Acid Drugs 0.000 description 1
- 230000036912 Bioavailability Effects 0.000 description 1
- 208000010392 Bone Fractures Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 210000000481 Breast Anatomy 0.000 description 1
- 206010006232 Breast disease Diseases 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate dianion Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 208000008787 Cardiovascular Disease Diseases 0.000 description 1
- 206010057668 Cognitive disease Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229960001681 Croscarmellose Sodium Drugs 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- 229960000913 Crospovidone Drugs 0.000 description 1
- 229910017488 Cu K Inorganic materials 0.000 description 1
- 206010011652 Cushing's syndrome Diseases 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N D-sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K Dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 206010013908 Dysfunctional uterine bleeding Diseases 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 210000004696 Endometrium Anatomy 0.000 description 1
- 210000000981 Epithelium Anatomy 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- BFPYWIDHMRZLRN-SLHNCBLASA-N Etivex Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 1
- 229960002598 Fumaric acid Drugs 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229960002989 Glutamic Acid Drugs 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010020583 Hypercalcaemia Diseases 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 206010020947 Hypocalcaemia Diseases 0.000 description 1
- 208000000509 Infertility Diseases 0.000 description 1
- TYQCGQRIZGCHNB-JLAZNSOCSA-N L-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(O)=C(O)C1=O TYQCGQRIZGCHNB-JLAZNSOCSA-N 0.000 description 1
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 1
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 229960000448 Lactic acid Drugs 0.000 description 1
- 206010024324 Leukaemias Diseases 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L Magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N Malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 206010025650 Malignant melanoma Diseases 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 208000003393 Mammary Paget's Disease Diseases 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- FEWJPZIEWOKRBE-XIXRPRMCSA-N Mesotartaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-XIXRPRMCSA-N 0.000 description 1
- IMSSROKUHAOUJS-MJCUULBUSA-N Mestranol Chemical compound C1C[C@]2(C)[C@@](C#C)(O)CC[C@H]2[C@@H]2CCC3=CC(OC)=CC=C3[C@H]21 IMSSROKUHAOUJS-MJCUULBUSA-N 0.000 description 1
- 229960001390 Mestranol Drugs 0.000 description 1
- 206010027514 Metrorrhagia Diseases 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 210000004400 Mucous Membrane Anatomy 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinylpyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 206010067572 Oestrogenic effect Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 208000010191 Osteitis Deformans Diseases 0.000 description 1
- 208000005368 Osteomalacia Diseases 0.000 description 1
- 206010049088 Osteopenia Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 241000283898 Ovis Species 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 238000001069 Raman spectroscopy Methods 0.000 description 1
- 206010038444 Renal failure chronic Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 229960005055 SODIUM ASCORBATE Drugs 0.000 description 1
- 206010040799 Skin atrophy Diseases 0.000 description 1
- 229940005550 Sodium alginate Drugs 0.000 description 1
- 240000001016 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 229960005137 Succinic Acid Drugs 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H Tricalcium phosphate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K Trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
- 206010046798 Uterine leiomyoma Diseases 0.000 description 1
- 206010046811 Uterine polyp Diseases 0.000 description 1
- 210000004291 Uterus Anatomy 0.000 description 1
- 229960002675 Xylitol Drugs 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N Xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 238000002679 ablation Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000000862 absorption spectrum Methods 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 159000000021 acetate salts Chemical class 0.000 description 1
- WEVYAHXRMPXWCK-UHFFFAOYSA-N acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 235000011037 adipic acid Nutrition 0.000 description 1
- 239000001361 adipic acid Substances 0.000 description 1
- 229960000250 adipic acid Drugs 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000005215 alkyl ethers Chemical class 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- WMGSQTMJHBYJMQ-UHFFFAOYSA-N aluminum;magnesium;silicate Chemical compound [Mg+2].[Al+3].[O-][Si]([O-])([O-])[O-] WMGSQTMJHBYJMQ-UHFFFAOYSA-N 0.000 description 1
- 201000000736 amenorrhea Diseases 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- 239000001099 ammonium carbonate Substances 0.000 description 1
- 235000012501 ammonium carbonate Nutrition 0.000 description 1
- 229940027983 antiseptics and disinfectants Quaternary ammonium compounds Drugs 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 239000008122 artificial sweetener Substances 0.000 description 1
- 235000010385 ascorbyl palmitate Nutrition 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000002146 bilateral Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000035514 bioavailability Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 235000011132 calcium sulphate Nutrition 0.000 description 1
- 238000007707 calorimetry Methods 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 230000000271 cardiovascular Effects 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 239000007810 chemical reaction solvent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 201000000522 chronic kidney disease Diseases 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 229960004106 citric acid Drugs 0.000 description 1
- 201000007368 coagulation protein disease Diseases 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000005712 crystallization Effects 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000003111 delayed Effects 0.000 description 1
- 230000002939 deleterious Effects 0.000 description 1
- 229940075894 denatured ethanol Drugs 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 238000001938 differential scanning calorimetry curve Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000009513 drug distribution Methods 0.000 description 1
- 238000007908 dry granulation Methods 0.000 description 1
- 201000009273 endometriosis Diseases 0.000 description 1
- 201000009274 endometriosis of uterus Diseases 0.000 description 1
- 235000010350 erythorbic acid Nutrition 0.000 description 1
- 239000004318 erythorbic acid Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 201000006564 estrogen excess Diseases 0.000 description 1
- 102000015694 estrogen receptors Human genes 0.000 description 1
- 108010038795 estrogen receptors Proteins 0.000 description 1
- 229960002568 ethinylestradiol Drugs 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000005755 formation reaction Methods 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 230000002710 gonadal Effects 0.000 description 1
- 239000008079 hexane Substances 0.000 description 1
- 239000008240 homogeneous mixture Substances 0.000 description 1
- 238000002657 hormone replacement therapy Methods 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 230000000148 hypercalcaemia Effects 0.000 description 1
- 230000000705 hypocalcaemia Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 231100000535 infertility Toxicity 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 229940026239 isoascorbic acid Drugs 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 201000009673 liver disease Diseases 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 239000011776 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 235000014380 magnesium carbonate Nutrition 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 229940099690 malic acid Drugs 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- 201000009251 multiple myeloma Diseases 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 238000009806 oophorectomy Methods 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 238000010525 oxidative degradation reaction Methods 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 230000036231 pharmacokinetics Effects 0.000 description 1
- 239000008196 pharmacological composition Substances 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 201000010065 polycystic ovary syndrome Diseases 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001184 potassium carbonate Substances 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 235000015320 potassium carbonate Nutrition 0.000 description 1
- 235000019814 powdered cellulose Nutrition 0.000 description 1
- 229920003124 powdered cellulose Polymers 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 201000009395 primary hyperaldosteronism Diseases 0.000 description 1
- 230000002035 prolonged Effects 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propanol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- BPQQTUXANYXVAA-UHFFFAOYSA-N silicate Chemical compound [O-][Si]([O-])([O-])[O-] BPQQTUXANYXVAA-UHFFFAOYSA-N 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- MSXHSNHNTORCAW-UHFFFAOYSA-M sodium 3,4,5,6-tetrahydroxyoxane-2-carboxylate Chemical compound [Na+].OC1OC(C([O-])=O)C(O)C(O)C1O MSXHSNHNTORCAW-UHFFFAOYSA-M 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 description 1
- 235000010378 sodium ascorbate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 235000011044 succinic acid Nutrition 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 230000001502 supplementation Effects 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- 229960001367 tartaric acid Drugs 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 230000001225 therapeutic Effects 0.000 description 1
- 230000001131 transforming Effects 0.000 description 1
- 239000011778 trisodium citrate Substances 0.000 description 1
- 235000019263 trisodium citrate Nutrition 0.000 description 1
- 230000001228 trophic Effects 0.000 description 1
- 201000007954 uterine fibroid Diseases 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 238000005550 wet granulation Methods 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
Abstract
The present invention is directed to a crystalline polymorph of bazedoxifene acetate, compositions containing the same, preparations thereof, and uses thereof.
Description
CRYSTALLINE POLYMORPHOST OF A BAZEDOX1FENO ACETATE
FIELD OF THE INVENTION
The present invention relates to a crystalline polymorph, designated form A, of the selective estrogen receptor modulator 1- [4- (2-azepan-1-yl-ethoxy) -benzyl] -2- (4-hydrox! feniI) -3-methyl-1 H-indol-5-olacetic acid (bazedoxifene acetate).
BACKGROUND OF THE INVENTION
Bazedoxifene acetate (1 - [4- (2-azepan-1-yl-ethoxy) -benzyl] -2- (4-hydroxy-phenyl) -3-methyl-1-H-indole-5-olacetic acid) , which has the chemical formula shown below:
It belongs to the class of drugs typically referred to as selective estrogen receptor modulators (SERMs). Consistent with its classification, bazedoxifene demonstrates affinity for receptors of
estrogen (ER) but shows selective tissue estrogenic effects. For example, bazedoxifene acetate demonstrates little or no stimulation of uterine response in preclinical models of uterine stimulation. In contrast, bazedoxifene acetate demonstrates an effect similar to the estrogen agonist in the prevention of bone loss and cholesterol reduction in an ovariectomized rat model of osteopenia. In a MCF-7 cell line (human breast cancer cell line), bazedoxifene acetate behaves as an estrogen antagonist. These data demonstrate that bazedoxifene acetate is estrogenic on bone and cardiovascular and antiestrogenic lipid parameters on uterine and breast tissue and therefore has the potential to treat a number of different diseases or disease-like conditions wherein the recipient of Estrogen is involved. The patents of E.U.A. Nos. 5,998,402 and 6,479,535 report the preparation of bazedoxifene acetate and characterize the salt as having a melting point of 174-178 ° C. The synthetic preparation of bazedoxifene acetate has also appeared in the general literature. See, for example, Miller et al, J Med. Chem., 2001, 44, 1654-1657, which reports salt as a crystalline solid having a melting point of 170.5-172.5 ° C. An additional description of the biological activity of the drug has also appeared in the general literature (eg Miller, et al., Drugs of the Future, 2002, 27 (2), 117-121). It is well known that the crystalline polymorph form of a
Particular drug is often an important determinant of the ease of preparation, stability, solubility, storage stability, ease of formulation and in vivo pharmacology of the drug. Polymorphic forms occur where the same material composition crystallizes in a different lattice arrangement resulting in different thermodynamic properties and specific stabilities for the particular polymorphic form. In cases where two or more polymorphic substances can be produced, it is desirable to have a method for making both polymorphs in pure form. When deciding which polymorph is preferable, one should compare the numerous properties of the polymorphs and the preferred polymorph chosen based on the many physical property variables. It is quite possible that a polymorph form may be preferable in some circumstances where certain aspects such as ease of preparation, stability, etc., are considered critical. In other situations, a different polymorph may be preferred for greater solubility and / or higher pharmacokinetics. Because improved drug formulations are consistently sought, which show, for example, better bioavailability or better stability, there is a current need for new or purer forms of existing drug molecules. The polymorph of bazedoxifene acetate described here helps meet these and other needs.
BRIEF DESCRIPTION OF THE DRAWINGS
Figure 1 illustrates a powder X-ray diffraction pattern of the A form polymorph of bazedoxifene acetate, wherein the diffraction angle (2T) varies from 5o to 40 ° with a step of 0.02 °. Figure 2 illustrates an IR spectrum of the form A polymorph of bazedoxifene acetate in KBr tablet. Figure 3 illustrates a differential scanning calorimetry (DSC) trace of the form A polymorph of bazedoxifene acetate. Figure 4 illustrates a DSC trace of the polymorph of form B of bazedoxifene acetate as a comparison.
BRIEF DESCRIPTION OF THE INVENTION
The present invention provides a crystalline polymorph (form A) of bazedoxifene acetate characterized in accordance with the powder X-ray diffraction data, IR data and DSC data provided herein. The present invention further provides compositions containing the form A of bazedoxifene acetate. The present invention further provides a method for preparing the polymorphic form A of bazedoxifene acetate comprising: a) reacting hexamethyleneiminobenzyloxyindole with a
hydrogenation reagent in a solvent and optionally in the presence of a hydrogenation catalyst for a time and under suitable conditions to form a reaction mixture comprising bazedoxifene free base; b) treating the reaction mixture with acetic acid for a time and under suitable conditions to form the polymorphic form A of bazedoxifene acetate. The present invention further provides a method for treating a mammal having a disease or syndrome associated with estrogen deficiency or excess estrogen comprising administering to said mammal a therapeutically effective amount of the form A polymorph of bazedoxifene acetate. The present invention further provides a method for treating a mammal having a disease or disorder associated with proliferation or abnormal development of endometrial tissues comprising administering to said mammal a therapeutically effective or polymorph amount of
A polymorph of bazedoxifene acetate. The present invention further provides a method for reducing cholesterol in a mammal comprising administering to said mammal a therapeutically effective amount of form A polymorph of bazedoxifene acetate. The present invention further provides a method for inhibiting bone loss or breast cancer in a mammal comprising
administering to the mammal a therapeutically effective amount of form A polymorph of bazedoxifene acetate. The present invention further provides a method for treating a postmenopausal woman for one or more vasomotor disturbances, such as hot flushing, which comprises administering to the postmenopausal woman a therapeutically effective amount of form A polymorph of bazedoxifene acetate. The present invention also provides form A of crystalline polymorph of bazedoxifene acetate prepared by any of the methods described herein. The present invention further provides the crystalline polymorph of the invention for use in therapy. The present invention also provides the use of the crystalline polymorph of the invention for the preparation of a medicament.
DETAILED DESCRIPTION OF THE INVENTION
The present invention provides an anhydrous, unsolvated crystalline polymorph of bazedoxifene acetate, referred to herein as Form A, which can be identified by one or more solid state analytical methods. For example, Form A can be identified by its powder X-ray diffraction pattern, which is provided in Figure 1. Powder X-ray diffraction data consistent with Form A is provided in Table 1
following.
TABLE 1
In some embodiments, the crystalline polymorph A form of bazedoxifene acetate is characterized by a powder X-ray diffraction pattern having characteristic peaks, in terms of 20, at about 12.7 ° and about 18.5 °. In further embodiments, the powder X-ray diffraction pattern further includes characteristic peaks, in terms of 2T, at approximately 16.0 °,
approximately 20.7 ° and approximately 22.3 °. In further embodiments, the X-ray powder diffraction pattern of Form A includes 5 or more characteristic peaks, in terms of 2T, selected from about 9.8 °, about 12.7 °, about 15.2 °, about 16.0 °, about 17.1 ° , approximately 17.4 °, approximately 18.5 °. approximately 18.8 °, about 19.6 °, about 20.4 °, about 20.7 °, about 22.3 °, about 23.5 °, about 24.9 °, about 25.6 °, about 26.1 °, about 27.4 °, about 28.0 °, about 28.7 °, about 29.6 °, about 29.9 ° and approximately 30.7 °. In further embodiments, Form A is characterized by a powder X-ray diffraction pattern substantially as shown in Figure 1. The relative intensities of the peaks may vary, depending on the technique of sample preparation, the procedure of assembly of the sample and particular instrument used. Moreover, the variation of instruments and other factors can affect the values of 2-theta. Therefore, XRPD peak assignments can vary by plus or minus approximately 0.2 °. Form A can also be identified by its characteristic infrared (IR) absorption spectrum as provided in Figure 2. In some embodiments, Form A is characterized by an infrared spectrum in KBr that has one or more characteristic peaks selected from approximately 1511, approximately 1467 and approximately 1242 cm "1.
Form A can also be identified by its characteristic differential calorimetry (DSC) scan trace as shown in Figure 3. In some embodiments, Form A is characterized by
a trace of DSC showing a maximum at approximately 176 ° C. For DSC, it is known that the temperatures observed will depend on the rate of
change of temperature as well as the technique of sample preparation and
the particular instrument used. Therefore, the values reported here in
relationship with DSC thermograms may vary by more or less
about 4 ° C. The polymorphic form A of baxedoxifene acetate is easily distinguishable from other crystalline polymorphs, such as the less soluble form B. The sample data for several physical properties are compared for the polymorphs of Form A and Form B, below in Table 2.
TABLE 2
Measurement Form A Form B Melting point 176 ° C 181 ° C Melting heat 94.6 J / G 108.4 J / G Solubility-water 0.49 mg / ml 0.23 mg / ml Solubility-organic 24.5 mg / ml 12.4 mg / ml (EtOH / EtOAc / Tol) Dissolution rate 0.125 mg / cm2-min 0.09 mg / cm2-min intrinsic DSC Fusion endotherm Individual individual fusion endotherm 176.1 ° C 181.1 ° C TGA Similar Similar X-ray powder 12.7 °, 16.0 °, 18.5 ° , 13.3 °, 20.8 °, 21.6 °, 20.7 °, 22.3 ° (2T) 25.0 ° (2T) Raman / IR 1511, 1467 cr? M 1513, 1449, 1406 cm -1
As can be seen in table 2, the two crystalline polymorphs have physical and spectroscopic characteristics that can not be separated. Form A appears to have higher solubility in aqueous and organic solvent systems than Form B, which is advantageous in particular formulations or dosages wherein the solubility of the particular composition is of concern. For example, the higher solubility may contribute to better biological absorption and drug distribution, as well as facilitate formulation in liquid vehicles. Form A can be prepared, for example, by deprotection of hexamethylenebenzyloxyindole (see, e.g., in U.S. Patent No.
,998,402) by hydrogenolysis in a solvent containing an alcohol (e.g., ethanol) in the presence of a hydrogenation catalyst (e.g., 10% palladium on carbon, 10% Pd / C). The hydrogenolysis can be carried out for any length of time and is typically carried out until the reaction is substantially complete as can be monitored by HPLC or any other suitable technique. The catalyst can be subsequently removed by filtration and an antioxidant (e.g., ascorbic acid) added to inhibit possible oxidative degradation of the hydrogenated product. Suitable exemplary weight ratios of the solvent to hexamethylenebenzyloxyindole include, for example, from about 10: 1 to about 2: 1, about 8: 1 to about 4: 1, or about 6: 1 to about 7: 1. Acetic acid can be added to the hydrogenated product (base
free of bazedoxifene), which forms the acetate salt. Suitable amounts of acetic acid are typically sufficient to convert all the free base present in the reaction mixture to the salt form. Accordingly, one or more equivalents of acetic acid can be added (in relation to the amount of hexamethylenebenzyloxyindole starting material). In some embodiments, about 1 to about 2 equivalents of acetic acid are added. The entire desired amount of acetic acid can be added in one or multiple portions. The crystalline product is typically precipitated from the solution with the addition of acetic acid and can be recrystallized from a solvent containing alcohol in accordance with routine methods. Suitable alcohols used in the methods of preparation and recrystallization may include, for example, methanol, ethanol, ethanol, isopropanol, mixtures thereof and the like. In some embodiments, the alcohol is ethanol which may optionally be denatured with approximately 1-10% v / v toluene, approximately 1-10% v / v hexanes, approximately 1-10% v / v ethyl acetate, and the like. In further embodiments, the reaction solvent and / or the recrystallization solvent is ethanol containing 5% (by volume) ethyl acetate. In additional embodiments, the solvent is ethanol. The steps involved in the preparation of Form A can be carried out at any suitable temperature, such as at or below
about 25, about 20 or about 15 ° C. For example, the hydrogenation can be carried out at room temperature such as 25 ° C. The addition of acetic acid can be carried out at about 20 ° C or less. The reaction mixture containing bazedoxifene acetate can be maintained for any length of time (e.g., at least about 1 hr, at least about 2 hr, at least about 6 hr, or at least about 12 hours). hr) at a temperature of about -20 to about 20 ° C. In some embodiments, the reaction mixture is maintained for at least 2 hours at 20 ° C. In some embodiments, the reaction mixture is maintained for at least about 2 hours at 0 ° C. The proportion of Form B, in a composition containing a mixture of Form A and Form B, can be increased in accordance with the following methods. For example, Form B may comprise less than about 10%, less than about 20%, less than about 30%, or less than about 40% by weight of total bazedoxifene acetate in the starting composition. The proportion of Form B can be increased by combining the solvent containing an alcohol with the starting composition and maintaining the resulting mixture at or above a temperature of about 25 ° C (e.g., from about 25 to about 60, from about 25 to about 40, or from about 25 to about 30 ° C)
for a suitable length of time to increase the proportion of Form B in the composition. The solvent can be supplied in an amount sufficient to dissolve substantially all or less than all of the starting material of bazedoxifene acetate to form homogeneous or heterogeneous mixtures, respectively. The solvent can be provided in a weight ratio of total solvent to amount of bazedoxifene starting material of, for example, about 5: 1, about 3: 1, about 2: 1, or about 1: 1. In some embodiments, the mixture of bazedoxifene acetate and solvent is heated to reflux temperature, such as for several hours (e.g., about 1 to about 3 hours) then cooled slowly in a stepwise manner. For example, the mixture can be cooled to about 45 to about 55 ° C (e.g., about 50 ° C) during the course of a first period and then cooled to about 10 to about 30 ° C (e.g. , approximately 20 ° C) during the course of a second period. The first, second, and any additional periods may vary over many hours such as from about 1 to about 5 hours or from about 1 to about 3 hours. In some modalities, the first period is approximately 1 hour and the second period is approximately 3 hours. The mixture can be further maintained at the cooled temperature (e.g., about 10 to about 30 ° C) for an additional period sufficient for the precipitation of the product. He
additional period may be, for example, from 2 hours to approximately 24 hours, from approximately 8 to approximately 18 hours, or approximately 13 hours. In some embodiments, Form A can be prepared by crystallizing bazedoxifene acetate from a solution comprising an alcohol wherein the solution is maintained at a temperature below about 20 ° C, below about 10 ° C, or below about 5 ° C. The alcohol may comprise methanol, ethanol, n-propanol, isopropanol, mixtures thereof and the like. In some embodiments, alcohol includes ethanol. Procedures for preparing Form A may also include seeding solutions containing bazedoxifene acetate with seed crystals of Form A, and procedures for preparing Form B may also include seeding solutions containing bazedoxifene acetate with crystals. of form B. An exemplary preparation of form A is provided in example 1. An example preparation of form B is provided in example 2. The methods for preparation of form A that are provided herein they can result in substantially pure Form A (v., compositions containing less than about 10%, less than about 5% or less than about 3% of Form B) as well as mixtures enriched in Form A (e.g., greater than about
50% form A in relation to form B). Accordingly, the present invention further provides compositions containing the form A. In some embodiments, at least about 50%, at least about 70%, at least about 80%, at least about 90%, at least about 95%, at least about 97%, at least about 98.0%, at least about 98.1%, at least about 98.2%, at least about 98.3%, at least about 98.4%, at least about 98.5%, at least about 98.6%, at least about 98.7%, at least about 98.8%, at least about 98.9%, at least about 99.0%, at least about 99.1%, at least about 99.2 %, at least about 99.3%, at least about 99.4%, at least about 99.5%, at least about 99.6%, at least about 99.7%, at least about 99.8%, or at least about 99.9 wt.% of total bazedoxifene acetate in a composition is present as form A, In further embodiments, the compositions of the present invention essentially consist of bazedoxifene acetate wherein at least about 95%, at least about 97%, at least about 98.0%, at least about 98.1%, at least about 98.2%, at least about 98.3%, at least about
98. 4%, at least about 98.5%, at least about 98.6%, at least about 98.7%, at least about 98: 8%, at least about 98.9%, at least about 99.0%, at least about 99.1%, at least about 99.2%, at least about 99.3%, at least about 99.4%, at least about 99.5%, at least about 99.6%, at least about 99.7%, at least about 99.8%, or at least about 99.9% by weight of the bazedoxifene acetate is present in the compositions as the form 1A. In some embodiments, the remaining bazedoxifene acetate is present as Form B or as an amorphous material. Respective amounts of polymorphic forms of bazedoxifene acetate in a composition can be determined by any suitable spectroscopic method, such as powder X-ray diffraction or DSC. The present invention further provides composition comprising the polymorph of the invention (Form A) and Form B. In some embodiments, the composition comprises from about 70 to about 90% by weight of Form A and from about 10 to about 30. % by weight of Form B, from about 75 to about 85% by weight of Form A and from about 15 to about 25% by Weight of Form B, from 78 to about 92% by Weight of Form A and from about 18 to about 22% in
weight of Form B, or about 80% by weight of Form A and about 20% by Weight of Form B. The present invention further provides composition comprising bazedoxifene acetate wherein from about 70% to about 90% by weight of the total bazedoxifene acetate in the composition is present as the polymorph of the invention (form A) and from about 10 to about 30% by weight of total bazedoxifene acetate in the composition is present as the form B, or in wherein from about 75% to about 85% by weight of total bazedoxifene acetate in the composition is present as the polymorph of the invention (form A) and from about 15 to about 25% by weight of total bazedoxifene acetate in the composition is present as Form B, or wherein from about 78% to about 82% by weight of total bazedoxifene acetate in the composition is present as the polymorph of the invention. (Form A) and from about 18 to about 22% by weight of total bazedoxifene acetate in the composition is present as Form B, or wherein about 80% by weight of total bazedoxifene acetate in the composition is present as the polymorph of the invention (Form A) and about 20% by weight of total bazedoxifene acetate in the composition is present as Form B The compositions containing the forms A and B can be prepared by any suitable method which includes the mixture of the A forms
and B substantially pure made, for example, in accordance with any of the procedures provided herein.
Methods As described in the patent of E.U.A. No. 5,998,402, bazedoxifene and salts thereof are selective estrogen agonists with affinity for the estrogen receptor. Unlike other types of estrogen agonists, bazedoxifene and salts thereof are antiestrogenic in the uterus and can antagonize the trophic effects of estrogen agonists in uterine tissues. Accordingly, bazedoxifene acetate polymorphs and compositions containing the same can find many uses related to the treatment of disease states or syndromes associated with an estrogen deficiency or an excess of estrogen. The polymorph can also be used in treatment methods for diseases or disorders that result from proliferation or abnormal development, actions or growth of endometrial tissue or similar to endometria! The present polymorphic form of bazedoxifene acetate has the ability to behave as an estrogen agonist by reducing cholesterol and inhibiting bone loss. Therefore, the polymorph is useful for treating many conditions resulting from estrogen effects and excess or deficiency of estrogen including osteoporosis, prosthetic hypertrophy, male pattern baldness, vaginal and skin atrophy, acne, dysfunctional uterine bleeding, endometrial polyps, breast disease
benign, uterine leiomyomas, adenomyosis, ovarian cancer, infertility, breast cancer, endometriosis, endometrial cancer, polycystic ovary syndrome, cardiovascular disease, contraception, Alzheimer's disease, cognitive decline and other CNS disorders, as well as certain cancers including melanoma, prostate cancer, colon cancer, CNS cancers, among others. In addition, these polymorphs can be used for contraception in pre-menopausal women, as well as hormone replacement therapy in postmenopausal women (such as to treat vasomotor disturbances such as hot flushing) or in other estrogen deficiency states where it would be beneficial estrogen supplementation. It can also be used in disease states where amenorrhea is advantageous, such as leukemia, endometrial ablation, chronic kidney or liver disease or diseases or coagulation disorders. The polymorph of the invention can also be used in methods of inhibiting bone loss. Bone loss often results from an imbalance in the formation of an individual from new bone tissues and the reabsorption of older tissues, leading to a net loss of bone. Said bone depletion occurs in a range of individuals, particularly in postmenopausal women, women who have undergone bilateral oophorectomy, those who receive or who have received prolonged corticosteroid therapies, those who experience gonadal dysginosis, and those who suffer from Cushing's syndrome. In special needs of
bone, including teeth and oral bone, replacement can also be addressed using these polymorphs in individuals with bone fractures, defective bone structures, and those receiving related bone surgeries and / or prosthetic implantation. In addition to the problems described above, the polymorph can be used in treatments of osteoarthritis, hypocalcemia, hypercalcemia, Paget's disease, osteomalacia, osteohalisteresis, multiple myeloma and other forms of cancer that have deleterious effects on bone tissues. It is understood that the methods of treatment of the diseases and syndromes listed herein involve administration to an individual in need of such treatment of a therapeutically effective amount of the polymorph of the invention, or composition containing the same. As used herein, by the term "treatment", in reference to a disease, it is understood that it refers to preventing, inhibit and / or alleviate the disease. As used herein, the term "individual" or "patient," used interchangeably, refers to any animal, including mammals, preferably mice, rats, other rodents, rabbits, dogs, cats, swans, cattle, sheep, horses or primates, and very preferably humans. As used herein, the phrase "therapeutically effective amount" refers to the amount of active compound or pharmaceutical agent that induces the biological or medicinal response in response to a tissue, system, animal, individual or human that is being sought by a researcher , vet,
physician or other clinician, which includes one or more of the following: (1) prevent the disease; for example, preventing a disease, condition or disorder in an individual who may be predisposed to the disease, condition or disorder but still does not experience or display the pathology or symptomatology of the disease; (2) inhibit the disease; for example, inhibiting a disease, condition or disorder in an individual who is experiencing or displaying the pathology or symptomatology of the disease, condition or disorder (ie, stopping or slowing down the later development of the pathology and / or symptomatology); and (3) alleviate the disease; for example, alleviating a disease, condition or disorder in an individual who is experiencing or displaying the pathology or symptomatology of the disease, condition or disorder (ie, reversing the pathology and / or symptomatology). Dosage and formulation The invention also includes pharmaceutical compositions that use one or more of the present polymorphs together with one or more pharmaceutically acceptable carriers, excipients, etc. Form A formulations of bazedoxifene acetate include therapeutically effective amounts that can be given in daily doses ranging from 0.1 mg to 1000 mg to a person in need thereof. The example dose ranges vary from 10 mg / day to approximately 600
mg / day or from 10 mg / day to approximately 60 mg / day. The dosage can be either in a single dose or two or more divided doses per day. Said doses may be administered in any manner that facilitates the entry of the compound into the bloodstream including oral, implant, parenteral (including intravenous, intraperitoneal and subcutaneous), vaginal, rectal and transdermal administration. In some embodiments, the formulations are administered transdermally, which includes all administrations through the body surface and internal linings of body passages including epithelial and mucosal tissues. Said administration may be in the form of a lotion, cream, colloid, foam, patch, suspension or solution. Oral formulations containing the present polymorph can comprise any conventionally used oral forms, including tablets, capsules, buccal forms, troches, lozenges and oral liquids, suspensions or solutions. The capsules may contain mixtures of the crystalline form A in the desired percentage together with any other polymorph (s) of bazedoxifene acetate or amorphous bazedoxifene acetate. Capsules or tablets of the desired crystalline form of the percentage of the desired composition can also be combined with mixtures of other active compounds or fillers and / or inert diluents such as pharmaceutically acceptable starches (e.g., corn starch, potato or tapioca), sugars, artificial sweetening agents, powdered celluloses, such as crystalline and microcrystalline celluloses, flours, gelatins, gums, etc.
Tablet formulations can be made by conventional compression, wet granulation or dry granulation methods and use pharmaceutically acceptable diluents (fillers), binding agents, lubricants, disintegrants, suspending agents or stabilizers, including, but not limited to, stearate magnesium, stearic acid, talcum, sodium lauryl sulfate, microcrystalline cellulose, calcium carboxymethylcellulose, polyvinylpyrrolidone, gelatin, alginic acid, acacia gum, xanthan gum, sodium citrate, complex silicates, calcium carbonate, glycine, dextrin, - sucrose, sorbitol, dicalcium phosphate, calcium sulfate, lactose, kaolin, mannitol, sodium chloride, talc, dried starches and powdered sugar. The oral formulations used herein may use delayed or time-released standard or spansul formulations. Suppository formulations can be made from traditional materials, including cocoa butter, with or without the addition of waxes to alter the melting point of suppositories, and glycerin. Water-soluble suppository bases can also be used, such as polyethylene glycols of various molecular weights. Exemplary excipient systems suitable for preparing formulations of the present polymorph include one or more fillers, disintegrants and lubricants. The filler component can be any filler component known in the art including, but not limited to, lactose, microcrystalline cellulose, sucrose, mannitol, calcium phosphate, carbonate
calcium, cellulose powder, maltodextrin, sorbitol, starch or xylitol. Disintegrants suitable for use in the present formulations can be selected from those known in the art, including pregelatinized starch and sodium starch glycolate. Other useful disintegrants include croscarmellose sodium, crospovidone, starch, alginic acid, sodium alginate, clays (e.g., Veegum or xanthan gum), cellulose floc, ion exchange resins or effervescent systems, such as those using acids. food (such as citric acid, tartaric acid, malic acid, fumaric acid, lactic acid, adipic acid, ascorbic acid, aspartic acid, erythorbic acid, glutamic acid and succinic acid) and an alkaline carbonate component (such as sodium bicarbonate, calcium carbonate, magnesium carbonate, potassium carbonate, ammonium carbonate, etc.). The disintegrants useful herein may comprise from about 4% to about 40% of the composition by weight, preferably from about 15% to about 35%, most preferably from about 20% to about 35%. The pharmaceutical formulations may also contain an antioxidant or a mixture of antioxidants, such as ascorbic acid. Other antioxidants that may be used include sodium ascorbate and ascorbyl palmitate, preferably together with an amount of ascorbic acid. An exemplary range for the antioxidant (s) is from about 0.5% to about 15% by weight, most preferably from about 0.5% to about 5% by weight.
An exemplary oral formulation contains the present polymorph and the following excipient systems: a) a filler and disintegrant together comprising from about 5% to about 82% by weight (w) of the total formulation, preferably between about 30% and about 80% of the formulation, wherein from about 4% to about 40% by weight of the total formulation comprises one or more pharmaceutically acceptable disintegrants; and b) a lubricant comprising from about 0.2% to about 10% of the composition (by weight), such as that selected from the group of magnesium stearate or other metal stearates (eg, calcium stearate or zinc stearate), fatty acid esters (e.g., sodium stearyl fumarate), fatty acids (e.g., stearic acid), fatty alcohols, glyceryl behenate, mineral oil, paraffins, hydrogenated vegetable oils, leucine, polyethylene glycols, metal lauryl sulfates and sodium chloride. A further excipient system may comprise: a) a filler and disintegrant together comprising from about 5.4% to about 89%, by weight or preferably from about 32.5% to about 87% by weight; and b) lubricant comprising from about 0.22% to about 10.9% by weight. The excipient systems can also use
optionally pharmaceutically acceptable humectants, slippers and antioxidants. Said systems may comprise: a) a filler and disintegrant together comprising from about 5% to about 82% by weight (w) of the total formulation, preferably between about 30% and about 80% of the formulation, wherein about 4 % to about 40% by weight of the total formulation comprises one or more pharmaceutically acceptable disintegrants; b) optionally, a wetting agent comprising from about 0.2 to about 5% of the composition (by weight), such as that selected from the group of sodium lauryl sulfate, polyoxyethylene sorbitan fatty acid esters, polyoxyethylene alkyl ethers, acid esters sorbitan fatty acid, polyethylene glycols, polyoxyethylene castor oil derivatives, sodium docusate, quaternary ammonium compounds, fatty acid sugar esters and fatty acid glycerides; c) a lubricant comprising from about 0.2% to about 10% of the composition (by weight), such as that selected from the group of magnesium stearate or other metal stearates (e.g., calcium stearate or zinc stearate) esters of fatty acid (eg, sodium stearyl fumarate), fatty acids (eg, stearic acid), fatty alcohols, glyceryl behenate, mineral oil, paraffins, hydrogenated vegetable oils, leucine, polyethylene glycols, metal lauryl sulfates and sodium chloride; Y
d) optionally, a slide comprising from about 0.1% to about 10% (by weight) of the final composition, the slider selected from those known in the art, including the group of silicon dioxide, talc, metal stearates, silicate calcium or metal lauryl sulfates. Additional excipient systems, in accordance with the present invention, may include, by weight: a) a filler and disintegrant together comprising between about 54% and about 80% of the formulation, with the disintegrating agent (s) in the same comprising from about 4% to about 40% by weight of the overall formulation; b) a wetting agent comprising between about 0.55% and about 2.5% of the formulation; c) a lubricant comprising between about 0.2% and about 5.5% of the formulation; and d) a slide comprising between about 0.1% and about 5.0% of the formulation. The above excipient systems also optionally contain an antioxidant component, e.g., ascorbic acid, at a concentration of from about 0.5% to about 5.0% by weight. Among the additional excipient systems of this invention are those comprising: a) a filler and disintegrant together comprising between
about 50% and about 87% of the formulation, wherein the disintegrant (s) therein comprises from about 25% to about 35% of the formulation, by weight; b) a wetting agent comprising between about 0.55% and about 2.7% of the formulation; c) a lubricant comprising between about 0.2% and about 5.5% of the formulation; d) a slide comprising between about 0.1% and about 5.5% of the formulation; and e) an antioxidarite component, such as ascorbic acid, in an amount of from about 0.5% to about 5.5% by weight. The percentages listed above for the filler, disintegrant, lubricant and other components are based on the final pharmaceutical composition. The remaining percentage of the final composition is composed of the active pharmacological agent (s) and optionally a pharmaceutically acceptable surface coating, such as a coating or capsule, as described herein. In some embodiments of this invention, the active pharmacological agent (s) comprises from about 0.5% to about 20%, by weight, of the final composition, most preferably from about 1% to about 5%, and the coating or capsule comprises up to about 8%, by weight, of the final composition. The formulations described herein can be used in an uncoated or unencapsulated solid form. In some modalities, the
Pharmacological compositions are optionally coated with a film coating, for example, comprising from about 0.3% to about 8% by weight of the overall composition. Film coatings useful with the present formulations are known in the art and generally consist of a polymer (usually a cellulose type of polymer), a colorant and a plasticizer. Additional ingredients such as wetting agents, sugars, flavors, oils and lubricants can be included in film coating formulations to impart certain characteristics to the film coating. The compositions and formulations herein can also be combined and processed as a solid, then placed in a capsule form, such as a gelatin capsule. Pharmaceutical compositions of bazedoxifene acetate can be formulated with steroidal estrogens, such as conjugated estrogens, USP. The amount of bazedoxifene acetate used in the formulation can be adjusted in accordance with the particular polymorph form or ratio of polymorph forms used, the amount and type of steroid estrogen in the formulation as well as the particular therapeutic indication being considered. In general, the bazedoxifene acetate of defined polymorphic composition ratio can be used in an amount sufficient to antagonize the effect of the particular estrogen at the desired level. The dose range of conjugated estrogens can be from about 0.3 mg to about 2.5 mg, about 0.3
mg at about 1.25 mg or about 0.3 mg to about 0.625 mg. An exemplary range for amount of bazedoxifene acetate in a combination formulation is from about 10 mg to about 40 mg. For the steroidal estrogen mestranol, a daily dose may be from about 1 μg to about 150 μg, and for ethinylestradiol a daily dose of about 1 μg to 300 μg may be used. In some embodiments, the daily dose is between about 2 μg and about 150 μg. In order that the invention described herein be understood more efficiently, examples are given below. It is to be understood that these examples are for illustrative purposes only and should not be considered as limiting the invention in any way.
EXAMPLES
EXAMPLE 1 Preparation of form A polymorph of bazedoxifene acetate
A 7.56-liter hydrogenation vessel with agitator was charged with hexamethyleneimino benzyloxyindole (250 g, 0.3841 mol, see US Patent No. 5,998,402 for one preparation), ethanol (denatured with 5% by volume ethyl acetate) (1578 g, 2000 ml), and 10% palladium on charcoal (25 g). The reagents were hydrogenated at 25 ° C and 3.5 kg / cm2 for 20 hours. The progress of the reaction was monitored by HPLC (Column: CSC-S ODS 2, 25 cm, mobile phase: 20% of 0.02 M NH4H2P04 (2 ml of TEA / L, pH = 3) and 80% of MeCN, Flow: 2 ml / min; Detector: 220 nm). The reaction was considered complete when less than 1% of the hexamethyleneimino benzyloxyindole (18.2 min retention time) or derivative was detected
mono-debenzylated thereof (5.1 min retention time). The mixture was filtered through a cartridge that was subsequently rinsed with ethanol (denatured with 5% by volume ethyl acetate) (2 x 198 g, 2 x 250 ml). The filtrate was transferred to a 5-liter multi-neck flask with agitator loaded with L-ascorbic acid (2.04 g, 0.0116 mol) under nitrogen. Acetic acid (34.6 g, 0.5762 mol) was added at 20 ° C while stirring. The resulting reaction mixture was stirred for 2 hours (the pH was about 5 and the crystallization started within about 10 minutes of addition of acetic acid). The reaction mixture was then cooled to 0 ° C and maintained at this temperature for 2 hours. The resulting solid was collected by filtration in a Buchner funnel and washed with ethanol (denatured with 5% by volume ethyl acetate) (2 x 150 g, 2 x 190 ml) at 0 ° C. The solid product was further purified by charging a 3-liter multi-necked flask (with stirrer, thermometer and condenser under nitrogen) with the filtered solid, ethanol (denatured with 5% by volume ethyl acetate) (1105 g, 1400 ml) , and L-ascorbic acid (1.73 g, 0.01 mol). The resulting mixture was heated to 75 ° C and cooled to 20 ° C over the course of 2 hours. The resulting suspension was further cooled to 0 ° C and kept at this temperature for 2 hours. The resulting solid product was collected by filtration with a Buchner funnel and washed with ethanol (denatured with 5% by volume ethyl acetate) (2 x 79 g, 2 x 100 ml) at 0 ° C. the product was dried under vacuum at 60 ° C, 5 mm Hg for 24 hours
giving 151.3 g of form A of bazedoxifene acetate (74.2% yield).
EXAMPLE 2 Preparation of form B of bazedoxifene acetate from Form A
To a stirred solution of 594 g of ethanol (denatured with
% acetone and 3% cyclohexane) and 184 g ethyl acetate, 400 g pure form A acetate of bazedoxifene were added under nitrogen (e.g., see Example 1). The heterogeneous mixture was maintained at 30 ° C and stirred overnight under nitrogen. The conclusion of the crystal transformation was determined by DSC analysis. The mixture was cooled to 0 ° C and stirred for 2 hr under nitrogen. The product was filtered, washed with a mixture of denatured ethanol and ethyl acetate as above and dried overnight at 60 ° C under vacuum to give 391 g (97.7% yield) of Form B polymorph of bazedoxifene acetate. A substantially identical result was obtained using absolute ethanol or ethanol denatured with 5% toluene.
EXAMPLE 3 Diffraction of X-ray powder (XRPD)
XRPD analysis (see, eg, FIG. 1) was carried out on a powder X-ray diffractometer (Scintag X2) using Cu K a radiation. The instrument was equipped with tube powder, and the amperage was set at 45 kV and 40 mA. The divergence and dispersion slots were fixed at 1 ° and the receiving slit was set at 0.2 mm. A continuous theta-two theta scrutiny was used at 37 min (0.4 sec / 0.02 ° step) from 3 to 40 ° 2T.
EXAMPLE 4 Infrared spectroscopy (IR)
IR spectra were acquired (see, e.g., figure 2) as follows. Samples were prepared as disks of potassium bromide (KBr) (or tablets). A small amount of each sample (approximately 3 mg) was ground in a hard surface mortar to a glossy appearance. Half a gram (0.5 g) of KBr was added to the sample and the mixture was ground continuously until well mixed. The mixture was then transferred to a die and pressed into a disk using a hydraulic press. The IR spectrum of Figure 2 was obtained using a DIGILAB EXCALIBUR Series FTS-4000 FT-IR spectrometer operated at a resolution of 4 cm "1 and 16 scrutinies between 400 - 4000 cm" 1.
EXAMPLE 5 Differential Scanning Calorimetry (DSC)
Measurements of DSC were made (see, eg, Figures 3 and 4) in both sealed tray and vented tray at a scanning speed of 10 ° C / min from 25 ° C to 200 ° C under purging of nitrogen using a Pyris I DSC from Perkin-Elmer. Various modifications of the invention, in addition to those described herein, will be apparent to those skilled in the art from the foregoing description. It is also intended that said modifications fall within the scope of the appended claims. Each reference cited in the present application is incorporated herein by reference in its entirety.
Claims (86)
1. A crystalline polymorph (form A) of bazedoxifene acetate having a powder X-ray diffraction pattern comprising characteristic peaks, in terms of 20, at about 12.7 ° and about 18.5 °.
2. The polymorph according to claim 1, further characterized in that the powder X-ray diffraction pattern further comprises characteristic peaks, in terms of 20, at approximately 16.0 °, approximately 20.7 ° and approximately 22.3 °.
3. The polymorph according to claim 1, further characterized in that the powder X-ray diffraction pattern comprises at least 5 characteristic peaks, in terms of 20, selected from about 9.8 °, about 12.7 °, about 15.2 °. about 16.0 °, about 17.1 °, about 17.4 °, about 18.5 °, about 18.8 °, about 19.6 °, about 20.4 °, about 20.7 °, about 22.3 °, about 23.5 °, about 24.9 °, about 25.6 °, about 26.1 °, approximately 27.4 °, approximately 28.0 °, approximately 28.7 °, approximately 29.6 °, approximately 29.9 ° and approximately 30.7 °.
4. - The polymorph according to claim 1, further characterized in that it has a powder X-ray diffraction pattern substantially as shown in figure 1.
5. The polymorph according to claim 1, further characterized by having a spectrum infrared in KBr comprising one or more selected characteristic peaks of about 1511, about 1467, and about 1242 cm "1.
The polymorph in accordance with claim 1, further characterized by having an infrared spectrum in KBr substantially as is shown in figure 2.
7. The polymorph according to claim 1, further characterized in that it has a trace of differential scanning calorimetry showing a maximum at about 176 ° C.
8. The polymorph in accordance with the claim 1, further characterized in that it has a trace of differential scanning calorimetry substantially as shown in figure 3.
9.- A composition comprising the polymorph of any of claims 1 to 8.
10. The composition according to claim 9, further characterized in that at least about 50% by weight of total bazedoxifene acetate in the composition is present as the polymorphous.
11. The composition according to claim 9, further characterized in that at least about 70% by weight of total bazedoxifene acetate in the composition is present as the polymorph.
12. The composition according to claim 9, further characterized in that at least about 80% by weight of total bazedoxifene acetate in the composition is present as the polymorph.
13. The composition according to claim 9, further characterized in that at least about 90% by weight of total bazedoxifene acetate in the composition is present as the polymorph.
14. The composition according to claim 9, further characterized in that at least about 95% by weight of total bazedoxifene acetate in the composition is present as the polymorph.
15. The composition according to claim 9, further characterized in that at least about 97% by weight of total bazedoxifene acetate in the composition is present as the polymorph.
16. The composition according to claim 9, further characterized in that at least about 98.0% by weight of total bazedoxifene acetate in the composition is present as the polymorph.
17. The composition according to claim 9, further characterized in that at least about 98.1% by weight of total bazedoxifene acetate in the composition is present as the polymorph.
18. The composition according to claim 9, further characterized in that at least about 98.2% by weight of total bazedoxifene acetate in the composition is present as the polymorph.
19. The composition according to claim 9, further characterized in that at least about 98.3% by weight of total bazedoxifene acetate in the composition is present as the polymorph.
20. The composition according to claim 9, further characterized in that at least about 98.4% by weight of total bazedoxifene acetate in the composition is present as the polymorph.
21. The composition according to claim 9, further characterized in that at least about 98.5% by weight of total bazedoxifene acetate in the composition is present as the polymorph.
22. The composition according to claim 9, further characterized in that at least about 98.6% by weight of total bazedoxifene acetate in the composition is present as the polymorph.
23. The composition according to claim 9, further characterized in that at least about 98.7% by weight of total bazedoxifene acetate in the composition is present as the polymorph.
24. The composition according to claim 9, further characterized in that at least about 98.8% by weight of total bazedoxifene acetate in the composition is present as the polymorph.
25. The composition according to claim 9, further characterized in that at least about 98.9% by weight of total bazedoxifene acetate in the composition is present as the polymorph.
26. The composition according to claim 9, further characterized in that at least about 99.0% by weight of total bazedoxifene acetate in the composition is present as the polymorph.
27. The composition according to claim 9, further characterized in that at least about 99.1% by weight of total bazedoxifene acetate in the composition is present as the polymorph.
28. The composition according to claim 9, further characterized in that at least about 99.2% by weight of total bazedoxifene acetate in the composition is present as the polymorph.
29. The composition according to claim 9, further characterized in that at least about 99.3% by weight of total bazedoxifene acetate in the composition is present as the polymorph.
30. The composition according to claim 9, further characterized in that at least about 99.4% by weight of total bazedoxifene acetate in the composition is present as the polymorph.
31. The composition according to claim 9, further characterized in that at least about 99.5% by weight of total bazedoxifene acetate in the composition is present as the polymorph.
32. The composition according to claim 9, further characterized in that at least about 99.6% by weight of total bazedoxifene acetate in the composition is present as the polymorph.
33. The composition according to claim 9, further characterized in that at least about 99.7% by weight of total bazedoxifene acetate in the composition is present as the polymorphous.
34. The composition according to claim 9, further characterized in that at least about 99.8% by weight of total bazedoxifene acetate in the composition is present as the polymorph.
35.- The composition according to claim 9, further characterized in that at least about 99.9% by weight of total bazedoxifene acetate in the composition is present as the polymorph.
36.- A composition comprising the polymorph of any of claims 1 to 9 (form A) and form B.
37.- The composition according to claim 36, further characterized in that it comprises from about 70 to about 90% by weight of Form A and from about 10 to about 30% by weight of Form B.
38.- The composition according to claim 36, further characterized in that it comprises from about 75 to about 85% by weight of Form A and about 15 to about 25% by weight of Form B.
39. The composition according to claim 36, further characterized in that it comprises from about 78 to about 92% by weight of Form A and from about 18 to about 22%. in weight of form B.
40. - The composition according to claim 36, further characterized in that it comprises about 80% by weight of Form A and about 20% by Weight of Form B.
41.- A composition comprising bazedoxifene acetate wherein from about 70% to about 90% by weight of total bazedoxifene acetate in said composition is present as the polymorph of claim 1 (form A) and from about 10 to about 30% by weight of acetate of total bazedoxifene in said composition is present as form B.
42. A composition comprising bazedoxifene acetate wherein from about 75% to about 85% by weight of total bazedoxifene acetate in said composition is present as the polymorph of the claim 1 (form A) and from about 15 to about 25% by weight of total bazedoxifene acetate in said composition is present as form B.
43.- A composition comprising bazedoxifene acetate wherein from about 78% to about 82 % by weight of total bazedoxifene acetate in said composition is present as the polymorph of claim 1 (form A) and of about 18 to about 22% by weight of total bazedoxifene acetate in said composition is present as form B.
44. A composition comprising bazedoxifene acetate wherein about 80% by weight of total bazedoxifene acetate in said composition is present as the polymorph of claim 1 (form A) and about 20% by weight of total bazedoxifene acetate in said composition is present as the form B.
45. A composition comprising the polymorph of any of the claims 1 to 8 and a pharmaceutically acceptable vehicle.
46.- A composition consisting essentially of bazedoxifene acetate wherein at least 95% by weight of said bazedoxifene acetate is present in the composition as the polymorph of any of claims 1 to 8.
47.- A composition consisting of essentially of bazedoxifene acetate wherein at least 97% by weight of said bazedoxifene acetate is present in the composition as the polymorph of any of claims 1 to 8.
48. A composition consisting essentially of bazedoxifene acetate wherein at least 98.0% by weight of said bazedoxifene acetate is present in the composition as the polymorph of any of claims 1 to 8.
49. A composition consisting essentially of bazedoxifene acetate wherein at least 98.1% by weight of said bazedoxifene acetate is present in the composition as the polymorph of any of claims 1 to 8.
50.- A composition that essentially of bazedoxifene acetate wherein at least 98.2% by weight of said acetate bazedoxifene is present in the composition as the polymorph of any of claims 1 to 8.
51. A composition consisting essentially of bazedoxifene acetate wherein at least 98.3% by weight of said bazedoxifene acetate is present in the composition as the polymorph of any one of claims 1 to 8.
52. A composition consisting essentially of bazedoxifene acetate wherein at least 98.4% by weight of said bazedoxifene acetate is present in the composition as the polymorph of any of the claims. 1 to 8.
53. A composition consisting essentially of bazedoxifene acetate wherein at least 98.5% by weight of said bazedoxifene acetate is present in the composition as the polymorph of any of claims 1 to 8.
54.- A composition consisting essentially of bazedoxifene acetate wherein at least 98.6% by weight of said bazedoxifene acetate is present in the composition as the polymorph of any of claims 1 to 8.
55.- A composition consisting essentially of bazedoxifene acetate wherein at least 98.7% by weight of said bazedoxifene acetate is present in the composition as the polymorph of any of claims 1 to 8.
56.- A composition consisting essentially of acetate of bazedoxifene wherein at least 98.8% by weight of said bazedoxifene acetate is present in the composition as the polymorph of any of claims 1 to 8.
57.- A composition consisting essentially of bazedoxifene acetate wherein at least 98.9 % by weight of said bazedoxifene acetate is present in the composition as the polymorph of any of claims 1 to 8.
58. A composition consisting essentially of bazedoxifene acetate wherein at least 99.0% by weight of said acetate bazedoxifene is present in the composition as the polymorph of any of claims 1 to 8.
59. A composition consisting essentially of bazedoxifene acetate wherein at least 99.1% by weight of said bazedoxifene acetate is present in the composition as the polymorph of any of claims 1 to 8.
60.- A composition consisting essentially of bazedoxifene acetate wherein at least 99.2% by weight of said bazedoxifene acetate is present in the composition as the polymorph of any of claims 1 to 8.
61.- A composition consisting of essentially of bazedoxifene acetate wherein at least 99.3% by weight of said bazedoxifene acetate is present in the composition as the polymorph of any of claims 1 to 8.
62. A composition consisting essentially of bazedoxifene acetate wherein at least 99.4% by weight of said bazedoxifene acetate is present in the composition as the polymorph of any of claims 1 to 8.
63. A composition consisting essentially of bazedoxifene acetate wherein at least 99.5% by weight of said bazedoxifene acetate is present in the composition as the polymorph of any of claims 1 to 8. 64.- A composition consisting essentially of bazedoxifene acetate wherein minus 99.6% by weight of said bazedoxifene acetate is present in the composition as the polymorph of any of claims 1 to 8. 65.- A composition consisting essentially of bazedoxifene acetate wherein at least 99.7% by weight of said Bazedoxifene acetate is present in the composition as the polymorph of any of claims 1 to 8. 66.- A composition that essentially of bazedoxifene acetate wherein at least 99.8 wt% of said bazedoxifene acetate is present in the composition as the polymorph of any of claims 1 to 8. 67. A composition consisting essentially of bazedoxifene acetate in wherein at least 99.9% by weight of said bazedoxifene acetate is present in the composition as the polymorph of any of claims 1 to 8. 68. A composition comprising the polymorph of any of claims 1 to 8 and one or more steroidal estrogens. 69.- The composition according to claim 68, further characterized in that the steroidal estrogen component comprises conjugated estrogens. A method for preparing the polymorphic form A of bazedoxifene acetate comprising: a) reacting hexamethyleneiminobenzyloxyindole with a hydrogenation reagent in a solvent and optionally in the presence of a hydrogenation catalyst for a time and under suitable conditions to form a reaction mixture comprising bazedoxifene free base; b) treating the reaction mixture with acetic acid for a time and under suitable conditions to form the polymorphic form A of bazedoxifene acetate. 71.- The method according to claim 70, further characterized in that the solvent comprises an alcohol. 72. The method according to claim 71, further characterized in that said alcohol comprises ethanol. 73.- The method according to claim 70 or claim 71, further characterized in that the solvent comprises ethyl acetate. 74.- The method according to any of claims 70 to 73, further characterized in that the reagent of Hydrogenation is H2. The method according to any of claims 70 to 74, further characterized in that the hydrogenation catalyst is Pd / C. The method according to any of claims 70 to 75, further characterized in that the treatment of step b) is carried out in the presence of an antioxidant. 77. The method according to claim 76, further characterized in that the antioxidant is ascorbic acid. 78. The method according to any of claims 70 to 77, further characterized in that the treatment of step b) is carried out at a temperature of about 25 ° C or less. The method according to any of claims 70 to 78, further characterized in that it comprises maintaining the reaction mixture of step b) at a temperature of about -20 to about 20 ° C for at least about 2 hours. The method according to any of claims 70 to 78, further characterized in that it comprises maintaining the reaction mixture of step b) at a temperature of about 20 ° C for at least about 2 hours. 81. The method according to any of claims 70 to 78, further characterized in that it comprises maintaining the reaction mixture of step b) at a temperature of about 0 ° C for at least 2 hours. 82. A method for preparing the polymorphic form A of bazedoxifene acetate comprising crystallizing bazedoxifene acetate from a solution comprising an alcohol wherein the solution is maintained at a temperature below about 20 ° C. 83. The method according to claim 82, further characterized in that the solution is maintained at a temperature below about 10 ° C. 84. The method according to claim 82 or 83, further characterized in that the alcohol is ethanol. 85.- The use of a polymorph as defined in any of claims 1 to 8 in the preparation of a medicament for the treatment of a mammal having a disease or syndrome associated with deficiency or excess of estrogen; or for the treatment of a mammal having a disease or disorder associated with the proliferation or abnormal development of endometrial tissues; or decrease of cholesterol in a mammal; or inhibition of bone loss in a mammal; or treatment of breast cancer in a mammal; or treatment of a menopausal woman for one or more vasomotor disturbances. 86.- The use claimed in claim 85, wherein the vasomotor disturbance is a shame.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US60/560,582 | 2004-04-07 | ||
US60/660,178 | 2005-03-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
MXPA06011716A true MXPA06011716A (en) | 2007-04-20 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7683051B2 (en) | Crystalline polymorph of bazedoxifene acetate | |
US7683052B2 (en) | Crystalline polymorph of bazedoxifene acetate | |
US7504394B2 (en) | Bazedoxifene ascorbate | |
JPH09512283A (en) | Anti-migraine indole derivative salts | |
JP2007532557A (en) | Bazedoxifene acetate solid dispersion formulation | |
CN1938272A (en) | Crystalline polymorph of bazedoxifene acetate | |
EP1880992A1 (en) | Stable modifications of tegaserod hydrogen maleate | |
MXPA06011716A (en) | Crystalline polymorph of a bazedoxifene acetate | |
MXPA06011717A (en) | Crystalline polymorph of bazedoxifene acetate | |
MX2007001510A (en) | Crystalline polymorph of pipindoxifene hydrochloride monohydrate. | |
MX2007001506A (en) | Crystalline polymorph of pipindoxifene hydrochloride monohydrate. |